Literature DB >> 24402104

Detection of podocyturia in patients with lupus nephritis.

Amelia Rodrigues Pereira Sabino, Vicente de Paulo Castro Teixeira, Sonia Kiyomi Nishida, Nelson Sass, Juliana Busato Mansur, Gianna Mastroianni Kirsztajn.   

Abstract

INTRODUCTION: The podocyturia has been detected in glomerular diseases, such as lupus nephritis (LN), in which proteinuria is an important manifestation, and its occurrence seems to be limited to the active phase of the disease.
OBJECTIVE: To evaluate podocyturia in LN patients, and the possible association with clinical disease activity.
METHODS: We evaluated 56 patients with LN, that were classified in three groups according to the degree of clinical activity: Group B, no activity (n = 17), Group C with mild (n = 29) and Group D, moderate to severe activity (n = 10). The control group was composed by 29 healthy subjects (Group A). The podocyturia was studied by indirect immunofluorescence using primary antibodies to podocyte: anti-podocin, nephrin and synaptopodin, and a secondary antibody conjugated with FITC. We also evaluated serum creatinine levels, urinary protein/creatinine (P/C) ratio, hematuria and leucocituria.
RESULTS: The podocyturia with anti-podocin and anti-sinaptopodin correlated statistically with the P/C ratio (p = 0.001 and p = 0.013, respectively). The podocyturia with anti-podocin, as well as the P/C ratio showed significant correlation (p < 0.001) with the degree of lupus disease activity, unlike the other two antibodies, anti-nephrin and anti-synaptopodin.
CONCLUSION: Our findings show that podocyturia with anti-podocin could be useful in monitoring disease activity in LN patients.

Entities:  

Mesh:

Year:  2013        PMID: 24402104     DOI: 10.5935/0101-2800.20130043

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN: 0101-2800


  5 in total

Review 1.  UCH-L1 Expressed by Podocytes: a Potentially Therapeutic Target for Lupus Nephritis?

Authors:  Ji-Hong Cui; Xin Xie
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

2.  Urinary podocalyxin as a marker of preeclampsia in a Hispanic population.

Authors:  Ylbe Palacios de Franco; Karina Velazquez; Natalia Segovia; Carolina Acosta; Deborah Yanosky; Ylbe V Franco Palacios; Amanda Ramos; Carlos R Franco Palacios
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2014-07-12

3.  Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.

Authors:  Hernán Trimarchi; Romina Canzonieri; Amalia Schiel; Juan Politei; Aníbal Stern; José Andrews; Matías Paulero; Tatiana Rengel; Alicia Aráoz; Mariano Forrester; Fernando Lombi; Vanesa Pomeranz; Romina Iriarte; Pablo Young; Alexis Muryan; Elsa Zotta
Journal:  J Nephrol       Date:  2016-02-03       Impact factor: 3.902

Review 4.  Fabry disease and kidney involvement: starting from childhood to understand the future.

Authors:  Roberto Chimenz; Valeria Chirico; Caterina Cuppari; Giorgia Ceravolo; Daniela Concolino; Paolo Monardo; Antonio Lacquaniti
Journal:  Pediatr Nephrol       Date:  2021-04-30       Impact factor: 3.651

5.  Increased urinary CD80 excretion and podocyturia in Fabry disease.

Authors:  H Trimarchi; R Canzonieri; A Schiel; C Costales-Collaguazo; J Politei; A Stern; M Paulero; T Rengel; J Andrews; M Forrester; M Lombi; V Pomeranz; R Iriarte; A Muryan; E Zotta; M D Sanchez-Niño; A Ortiz
Journal:  J Transl Med       Date:  2016-10-13       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.